Oncology

Targeting cancer at the molecular level through nuclear medicine, 3B Pharmaceuticals GmbH is a privately held pharmaceutical R&D company headquartered in Berlin, Germany. The company's work sits at the intersection of imaging, therapy, and theragnostics, disciplines that together define the emerging field of targeted radiotherapy . The company maintains an active pipeline of radiopharmaceutical assets, referred to internally as 3BP Assets, with programmes progressing through clinical trials. Its technology platform spans the development and application of radiopharmaceuticals and isotopes, providing the scientific foundation for both diagnostic imaging and therapeutic interventions. This dual imaging-and-therapy capability, known as theragnostics, positions the company within one of the more technically demanding areas of modern oncology drug development. Partnering is an explicit part of the company's model, and 3B Pharmaceuticals engages with external collaborators to advance its pipeline. Its published research contributes to the broader scientific literature on nuclear medicine, reflecting the R&D intensity of its operations. The company operates from its Berlin facility and is reachable through a named contact and directions infrastructure on its site, indicating an active, functioning organisation. For industry professionals, investors, or prospective partners working in nuclear medicine or radiopharmaceutical development, 3B Pharmaceuticals represents a focused, specialist player in a sector attracting considerable strategic interest across the global pharmaceutical industry. Further information is available at 3b-pharma.com.

ABX-CRO operates as an independent full-service contract research organisation with a declared specialism in neuroscience, oncology and molecular imaging, applying a translational medicine approach to take compounds from early bench research through to clinical bedside application. The organisation's formal name, ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, reflects its German origins, and its footprint has expanded internationally through both organic growth and strategic acquisitions. The service portfolio spans the full drug development continuum. On the clinical side, ABX-CRO provides radiopharmaceutical clinical trials , clinical operations, medical monitoring, pharmacovigilance, data management and biostatistics. Complementing these, the organisation offers imaging and dosimetry services alongside regulatory affairs support, preclinical and pharmacy capabilities, and project design and strategy consultancy. Medical device studies are also within scope. Several milestones mark the company's recent expansion. ABX-CRO acquired ClinSmart LLC, a Pennsylvania-based clinical quality CRO described as well-established, extending its North American presence. In India, the company secured official registration and accreditation with CDSCO as a radiopharmaceutical CRO , enabling it to conduct radiopharmaceutical clinical trials in that market. Recognition from the scientific community has also followed: ABX-CRO and Isotope Technologies Munich jointly received the Marie Curie Award from the European Association of Nuclear Medicine (EANM), acknowledging their collaborative work in the nuclear medicine field. The organisation additionally maintains an India office and a jobs programme, indicating sustained operational investment across multiple geographies. Further information is available at abx-cro.com.

With more than two decades of experience accelerating clinical development for emerging biotech companies, Accelsiors operates as a full-service global Contract Research Organisation (CRO) built specifically around the needs of smaller, agile biopharma developers. The company positions itself as a strategic partner rather than a transactional vendor, offering smart, tailored solutions across the full development continuum. Accelsiors delivers an extensive range of clinical trial services covering early-stage and late-stage development. Early-stage capabilities include project management, central and risk-based monitoring, regulatory monitoring and site management, data management, record management, safety management and pharmacovigilance, quality assurance, biostatistics, medical writing, and clinical pharmacology including modelling and simulation. Late-phase services extend to real-world evidence trials, with dedicated consultancy arms covering regulatory, medical and pharmacovigilance, legal and GDPR, and drug development consultancy. A functional service provider (FSP) model is also available for clients seeking embedded expertise rather than full outsourcing. The company serves a broad span of therapeutic areas , including oncology, autoimmune disorders, infectious diseases, endocrinology, respiratory, hepatology and gastrointestinal, nervous system, nephrology, women's health, nephrology, biosimilars, generics, paediatrics, cell and gene therapy, vaccines, orphan disorders, and microbiome research. This breadth reflects the company's positioning as a single-partner solution for biotech pipelines spanning multiple indications. Accelsiors has developed a suite of proprietary methodologies and platforms, among them Hexa-Helix, Quality Drive, StrongCORE Scientific, AcceleROUTE, WideSCOPE Intelligence, ProPATIENT Solutions, and AcceShield, each designed to support specific functions within the clinical development workflow. Further information is available at accelsiors.com.

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Acino operates as a speciality pharmaceutical company with a deliberate focus on emerging and underserved markets, channelling its commercial and manufacturing capabilities into regions including Africa, Latin America, the Middle East, Turkiye, North Africa, Ukraine, and the broader Eurasian corridor. This geographic strategy positions the Swiss-headquartered group where established multinationals have historically had thinner reach. The company's operational model spans three integrated pillars: partnering arrangements with third-party rights holders, in-house manufacturing supported by dedicated manufacturing sites, and direct product marketing. Quality assurance and supplier governance are identified as components of the manufacturing framework, reflecting the compliance requirements that apply across international markets. Acino's therapeutic portfolio addresses conditions prevalent in the markets it serves. Disease areas covered include cardiovascular disease, hypertension, infectious diseases, acid reflux, Helicobacter pylori infection, colorectal cancer, and narcolepsy. The company also maintains patient-facing health information on these conditions, indicating a level of engagement beyond the purely commercial. Counterfeit medicines awareness is included among its health matter communications, a consideration of particular relevance in markets with complex distribution environments. Sustainability forms part of the company's published agenda, alongside career development and media engagement, suggesting an organisation structured for long-term presence in its chosen regions rather than opportunistic market entry. Further information is available at acino.swiss.

Focused exclusively on the treatment of muscle wasting disorders , Actimed Therapeutics is advancing a pipeline of novel compounds targeting cancer-related cachexia and related conditions for which no globally approved pharmaceutical treatment currently exists. The clinical-stage biotechnology company aims to transform care for a patient population that has historically been under-served, with a stated goal of prolonging and improving quality of life, restoring dignity, and easing the burden on patients, carers, and healthcare providers alike. Cancer-related cachexia is a progressive wasting syndrome that accompanies cancer and other serious chronic illnesses. It is associated with significant morbidity and mortality, yet despite its prevalence and devastating clinical impact, therapeutic options remain very limited. Actimed Therapeutics has positioned itself at the frontier of this unmet medical need. The company's pipeline centres on two investigational agents: S-pindolol benzoate (ACM-001.1) and S-oxprenolol (ACM-002), both of which are being explored in the context of cachexia, cancer cachexia, muscle optimisation in obesity, and amyotrophic lateral sclerosis. The dual-compound approach reflects a broadening scientific focus on anabolic and anti-catabolic mechanisms in muscle biology. Governance includes a board, management team, founders, and an advisory panel, indicating an organised leadership structure appropriate to a company at this stage of development. Actimed Therapeutics operates with a clear patient-centred mission, directing its research towards conditions where conventional medicine has yet to deliver a definitive solution. Further information is available at actimedtherapeutics.com.

A proprietary antibody engineering platform sits at the core of Adagene , a Nasdaq-listed, clinical-stage immunotherapy company working to redefine how antibodies are discovered and designed for cancer treatment. Operating globally, the company has built its approach around the Dynamic Precision Library , a computational and structural biology platform that generates antibody candidates with enhanced precision and therapeutic potential. Three distinct antibody modalities underpin the platform. NEObody candidates are designed to access previously undruggable epitopes; SAFEbody molecules incorporate a masking mechanism intended to improve the therapeutic window; and POWERbody formats are engineered for potentiated immune engagement. Together, these technologies give Adagene a differentiated toolkit for addressing difficult oncology targets. The company's clinical pipeline includes ADG126, ADG116, ADG206 and ADG106, each progressing through clinical evaluation as part of a broader portfolio that also encompasses preclinical programmes. Adagene pursues its development objectives both independently and through external collaborations, reflecting a partnered model that extends the reach of its platform across the industry. As a public company listed on Nasdaq, Adagene operates under the governance and disclosure standards associated with that market, with oversight from a board of directors and a scientific and strategic advisory board. The organisation's commitment to antibody innovation positions it within the competitive immuno-oncology space, where platform differentiation and clinical progress are the key measures of progress. Further information is available at adagene.com.

Adaptimmune is built around a singular conviction: that engineered T-cells can be directed to fight cancer with precision and durability. The clinical-stage biopharmaceutical company focuses exclusively on cancer immunotherapy , developing cell therapies designed to arm a patient's own immune system against malignant disease. The company's pipeline has centred on next-generation T-cell receptor (TCR) therapies. Its named programmes include TECELRA, lete-cel, afami-cel, and uza-cel, all of which have been the subject of significant corporate activity. Adaptimmune announced the sale of these four cell therapies to US WorldMeds, a transaction that marks a strategic inflection point for the organisation and underscores the commercial value of its therapeutic assets. Trading on the Nasdaq under the ticker ADAPY, Adaptimmune has operated as a publicly listed entity, giving investors and industry partners visibility into its governance, pipeline progress and financial position. Its focus on T-cell receptor therapy places it within a specialised and competitive segment of oncology drug development, where target specificity and manufacturing scalability remain defining challenges. As a clinical-stage business, Adaptimmune's work sits at the intersection of translational science and commercial development, with programmes advancing from research through to patient-facing trials. The company publishes its pipeline status and scientific findings openly, providing industry professionals and research partners with access to its methodology and clinical data. Further information is available at adaptimmune.com.

Founded in 2021 and headquartered in San Diego, California, Adcentrx Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer and other life-threatening diseases. The company's work centres on its proprietary i-Conjugation platform, which addresses the principal engineering challenges of ADC design, including stable conjugation chemistry, cleavable linker technology, and controlled drug-antibody ratio (DAR 8), to maximise payload delivery to solid tumour cells while limiting systemic toxicity. Clinical Pipeline Adcentrx has advanced two candidates into Phase 1a/b clinical trials. ADRX-0706 is a Nectin-4 ADC currently in Phase 1b evaluation across a range of advanced solid tumours; the US FDA has granted it Fast Track Designation for locally advanced or metastatic squamous cell cervical cancer. ADRX-0405 is a STEAP1-targeting ADC in Phase 1a evaluation for metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer; it carries FDA Orphan Drug Designation for gastric cancer and is regarded as a potential first-in-class candidate for its target. Both programmes build on the i-Conjugation platform's aim to deliver best-in-class or first-in-class ADCs with differentiated clinical profiles. Funding & Partnerships Adcentrx has raised approximately $101 million across three financing rounds, including a Series A+ of $51 million led by Eight Roads Ventures and extended with participation from Quan Capital and Partners Investment. The company has entered a multi-target antibody discovery collaboration with AvantGen to source novel antibody candidates for its ADC pipeline. Further information is available at adcentrx.com.

Founded in Edinburgh in 2017, AdoRx Therapeutics is a clinical-stage oncology drug discovery company built around a single well-validated biological insight: high concentrations of adenosine within the tumour microenvironment allow cancer cells to evade immune surveillance. The company designs small-molecule adenosine receptor antagonists intended to disrupt that immune evasion and restore anti-tumour activity. Pipeline and Scientific Platform AdoRx focuses on two mechanistic targets: selective antagonists of the adenosine A2A receptor and dual-blockade compounds targeting both A2A and A2B receptors simultaneously. The dual-blockade approach is designed to address the redundancy that can limit single-target therapies in the adenosine pathway. The leadership team brings more than 60 years of combined drug-discovery experience across biotech and pharma, having collectively contributed to the identification of over 25 clinical candidates. Funding and Partnerships The company was seeded with $10 million in initial funding from Epidarex Capital and Sixth Element Capital, both specialist life-sciences investors. In 2019, AdoRx secured a strategic collaboration with Johnson Johnson Innovation and the Lung Cancer Initiative at Johnson Johnson, under which J J received an exclusive option to research, develop and commercialise novel adenosine antagonists from the AdoRx portfolio. The partnership underscores the scientific and commercial credibility of the company's immuno-oncology platform. Further information is available at adorx.com.

Listed on Nasdaq under the ticker AEZS, Aeterna Zentaris is a specialty pharmaceutical company with a commercial and clinical focus on endocrinology and oncology. Headquartered in Charleston, South Carolina, the company traces its origins to the Canadian biotech Aeterna Laboratories, which merged with the German firm Zentaris GmbH to form its current identity. This transatlantic background informs a development philosophy that blends North American regulatory strategy with European scientific heritage. The company's most recognised commercial asset is Macrilen (macimorelin), an oral growth hormone deficiency diagnostic approved by the US Food and Drug Administration and the European Medicines Agency. Macimorelin is the first and only orally active ghrelin receptor agonist indicated for the diagnosis of adult growth hormone deficiency, offering clinicians a more convenient alternative to traditional stimulation tests that require intravenous administration. Beyond its diagnostic franchise, Aeterna Zentaris has historically pursued oncology programmes targeting hormonal cancers, including compounds evaluated in adrenocortical carcinoma and endometrial cancer. The company operates a lean commercial model, partnering with regional distributors and licensing counterparts to extend the reach of its approved diagnostics without maintaining a large direct sales infrastructure. As a publicly traded entity subject to SEC reporting requirements, Aeterna Zentaris provides regular updates on its financial position, pipeline status, and commercial activities through filings available on the US Securities and Exchange Commission's EDGAR platform and through its corporate investor relations channels. Further information is available at zentaris.com.

Combining mobile nursing , teletrials and a dedicated oncology unit, Affinity Clinical Research Services brings clinical research capability directly to patients across Perth and the wider Australian continent. Operating from Doubleview in Western Australia and from a research facility within Hollywood Private Hospital Medical Centre, the organisation serves pharmaceutical sponsors, biotechnology companies and independent investigators seeking a flexible, patient-centred site partner. Affinity's service model covers the full research lifecycle, from protocol development and site feasibility through participant recruitment, data collection and publication support. The company's direct-to-patient and mobile trial services reduce the burden on participants who would otherwise be unable to access a fixed trial site, extending sponsor reach into regional and rural populations. This approach aligns with ICH-GCP guidelines and is adapted to the specific needs of each patient group and study design. The dedicated oncology division, Affinity Oncology, was established in 2016 and draws on clinical staff with more than a decade of experience in cancer trials. On-site resources include PET/CT imaging, a compounding pharmacy and a chemotherapy infusion suite, allowing complex oncology studies to run without reliance on third-party facilities. Beyond oncology, Affinity supports studies across a broad range of therapeutic areas and can assist private investigators running sponsor-initiated or investigator-initiated research. Further information is available at affinityresearch.com.au.